Systemic Sclerosis: Molecular Research and Novel Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 20 August 2024 | Viewed by 44
Special Issue Editor
Special Issue Information
Dear Colleagues,
Systemic sclerosis (SSc) is a rare chronic autoimmune connective tissue disease characterized by diffuse fibrosis of the skin and internal organs and vascular abnormalities, with a prevalence of 1.47 million people worldwide (https://doi.org/10.1016/j.clim.2023.109267). The mortality rate for this disease is higher than that of other rheumatic diseases, with no cure or drug that can stop progression. Like other autoimmune diseases, systemic sclerosis occurs more frequently in women, with a peak of onset during the fifth decade of life. SSc is a rare disease and there is great heterogeneity between patients in terms of the onset, progression and characteristics. This makes diagnosis and targeted treatment even more difficult. Pathogenesis is dominated by vascular changes, autoimmunity with distinct autoantibodies and the activation of both innate and adaptive immunity. The cause of systemic sclerosis is still unknown. However, it is believed that during the early stages of the disease, an over-reactive immune system causes systemic inflammation and injury to the endothelial cells of blood vessels. The unstoppable progression of vascular and fibrotic organ damage accounts for the chronic morbidity and ensuing high mortality.
The management of SSc has improved and there is an increasing number of randomized clinical trials, with new triggers, molecular pathways and drugs emerging. Data from these trials suggest a significant potential for several new therapeutic options for SSc in the near future. Combining drugs with immunomodulatory, vascular remodeling and antifibrotic properties to address the three main features that lead to sustained disease exacerbation may be an option.
This Special Issue is dedicated to molecular research and novel therapy necessary for attaining better knowledge about the diagnosis, prognosis and treatment of SSc.
Dr. Carole Nicco
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- systemic sclerosis
- rare disease
- T cells
- interstitial lung disease
- autoimmunity
- fibrosis
- connectivitis
- diffuse cutaneous systemic sclerosis
- interstitial lung disease
- pulmonary function test
- scleroderma
- digital ulcers
- myocardial fibrosis
- interstitial fibrosis
- rheumatoid lung disease
- systemic disease
- primary biliary cholangitis
- Raynaud syndrome
- biomarkers
